Loading...
•
Jun 30, 2020
Celsion Q2 2020 Earnings Report
Celsion reported a net loss and provided an update on clinical development programs with GEN-1 and ThermoDox.
Key Takeaways
Celsion reported a net loss of $5.3 million for the second quarter of 2020. The company is continuing to follow patients in the Phase III OPTIMA study for overall survival and initiated a Phase II study of GEN-1 in advanced ovarian cancer.
GEN-1 continues to show encouraging results in the OVATION 2 Study.
The Data Safety Monitoring Board recommended the Phase II portion of the OVATION Study proceed with the dose of 100 mg/m2.
Celsion received a recommendation from the independent Data Monitoring Committee to consider stopping the global Phase III OPTIMA Study.
Celsion will continue following patients for overall survival in the Phase III OPTIMA Study.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...